Table 3.

Crude and adjusted HR for outcomes among Anti-androgen alone, and CAB.

Variable	Control	Anti-androgen	Crude HR (95% CI)	Adjusted HR (95% CI)a	CAB	Crude HR (95% CI)	Adjusted HR (95% CI)a
	Rate, per 1000 person-years	Rate, per 1000 person-years			Rate, per 1000 person-years
DVT
1 year	3.42	2.69	1.35 (0.47–3.87)	1.17 (0.39–3.49)	2.76	1.49 (0.39–5.72)	1.27 (0.31–5.13)
2 year	0.55	3.50	6.46 (1.43–29.2)*	6.38 (1.28–31.7)*	3.32	6.13 (1.24–30.4)*	5.25 (0.94–29.5)
3 year	1.56	3.39	2.17 (0.74–6.34)	1.45 (0.48–4.36)	6.45	4.12 (1.43–11.9)**	2.02 (0.67–6.09)
4 year	1.12	0.39	0.35 (0.04–3.33)	0.26 (0.03–2.63)	2.73	2.44 (0.55–10.9)	2.14 (0.43–10.7)
5 year	1.43	1.44	1.01 (0.20–5.00)	0.90 (0.14–5.64)	0.00	NA	NA
PE
1 year	0.98	1.79	6.00 (0.81–44.2)	4.73 (0.60–37.0)	0.00	NA	NA
2 year	0.00	0.64	NA	NA	1.66	NA	NA
3 year	0.31	0.00	NA	NA	1.17	3.78 (0.34–41.7)	4.04 (0.19–87.2)
4 year	0.37	1.16	3.09 (0.32–29.7)	1.53 (0.16–14.9)	1.36	3.63 (0.33–40.0)	1.72 (0.14–20.6)
5 year	0.95	0.00	NA	NA	0.86	0.90 (0.08–9.95)	1.63 (0.11–24.3)

*p < 0.05; **p < 0.01.

^aAdjusted for all variables listed in Table 1.